AmSurg receives ‘strong buy’ rating for the short term: 4 facts

Zacks analysts gave AmSurg a “strong buy” rating for the short term, according to Money Flow Index.

Advertisement

Here are four facts:

1. On Monday, AmSurg shares traded at $83.38, down nearly 0.2 percent.

2. The 52-week high is $84.42 and 52-week low is $48.49.

3. The company has a market cap of nearly $4.04 billion.

4. AmSurg’s mean short term price target is $87.33 per share.

More articles on surgery centers:
Tenet Healthcare receives $40 price target: 5 takeaways
Alliance HealthCare Services, PRC Associates joint venture for interventional pain management: 5 things to know
16 hospitals & health systems opening ASCs — Nov. 10, 2015

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.